In the latest fallout from a federal probe into generic drug price fixing, Apotex agreed to pay $24 million to resolve criminal charges of conspiring with other manufacturers, the fourth company to be charged as part of the long-running investigation.
The company, which is based in Canada and is one of the world’s largest generic purveyors, admitted to working with several rivals to set prices for pravastatin, a commonly prescribed cholesterol medication, between 2013 and 2015, according to the U.S. Department of Justice.
About the Author Reprints
